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Abstract  
Introduction: The use of adjuvant treatment (AT) in resected biliary tract cancers (BTC) is 
still controversial. No efficacy comparison has been performed between chemotherapy 
(CT) and chemoradiotherapy (CTRT). A systematic review of the available evidence 
regarding adjuvant chemotherapy (AC) in resected BTC was performed. 
Methods: PubMed, EMBASE, Web of Science, SCOPUS and The Cochrane Library 
databases were searched for relevant articles published. Only studies including at least 50 
patients affected by tumors of gallbladder, intrahepatic, perihilar, and distal bile ducts 
were considered. Data were pooled using a random-effects model. The primary endpoint 
of the study was overall survival (OS).  
Results: Thirty studies were analyzed with a total of 22499 patients, 3967  of whom 
received AC. Eleven cohorts included Western patients and 19 were Asiatic. Surgeries 
were classified as R0 with negative margins, R1 with positive microscopic and R2 with 
positive macroscopic margins. Weighted mean OS difference among experimental (AC) 
and control arm was 4.3 months (95%CI 0.88-7.79, P=0.014). AC reduced the risk of death 
by 41% (Hazard ratio [HR] =0.59, 95%CI 0.49-0.71; P<0.001). 
Conclusions: AC administration gives an OS benefit in resected BTC. The results of 
prospective randomized studies are awaited in order to define the standard AT in BTC. 
Key words: cholangiocarcinoma, adjuvant chemotherapy, survival, meta-analysis 
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Introduction  
Biliary tract cancers (BTC) represent a heterogeneous group of neoplasms that includes 
gallbladder cancer and cholangiocarcinoma. Surgery is the only potentially curative 
treatment. However, despite radical resection, prognosis is poor and relapse frequent. 
Adjuvant treatment (AT) intended as chemotherapy (CT), radiotherapy (RT) and 
combination therapies may decrease the relapse rate and improve overall survival (OS) 
but its role is not clear yet because of the lack of conclusive data coming from randomized 
studies (1). 
Available guidelines (National Comprehensive Cancer Network [NCCN] (2) and 
European Society of Medical Oncology (3) guidelines (3)) consider multiple different AT 
options. Fluoropirimidine or gemcitabine based chemotherapy and fluoropyrimidine-
based chemoradiation are all suitable therapies for high-risk patients. 
The largest available meta-analysis of published studies reported an advantage in OS 
given by AT in BTC even if only 3 studies used CT alone as AT. The greatest improvement 
OS happened when CT and chemoradiotherapy (CTRT) were administered especially in 
patients with node positive and margin positive (R1) disease (1).  
Altough combination CTRT and CT are valid treatment alternatives, the use of 
concomitant RT may bring higher toxicities and a reduced tolerability. Therefore the aim 
of this study was to analyze the effect of adjuvant chemotherapy (AC), in order to 
investigate the possible OS advantage for patients undergoing resection for BTC. 
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Material and methods  
Search strategy and selection criteria  
Literature searches of PubMed, EMBASE, Web of Science, SCOPUS and The Cochrane 
Library were performed and all the studies published from the first available item until 
December 2016 were considered. Searches were limited to human studies and English-
language publications. The main keywords used for the PubMed search were 
(("gallbladder"[MeSH Terms] OR "gallbladder"[All Fields]) OR biliary [All Fields] OR 
("cholangiocarcinoma"[MeSH Terms] OR "cholangiocarcinoma"[All Fields])) AND 
("chemotherapy, adjuvant"[MeSH Terms] OR ("chemotherapy"[All Fields] AND 
"adjuvant"[All Fields]) OR "adjuvant chemotherapy"[All Fields] OR ("adjuvant"[All Fields] 
AND "chemotherapy"[All Fields])) AND ("mortality"[Subheading] OR "mortality"[All 
Fields] OR "survival"[All Fields] OR "survival"[MeSH Terms]). 
 Eligible trials included at least 50 patients with BTC (ampullary tumors only were 
excluded). AC was defined as mono or polychemotherapy administered after curative-
intent surgery. Adjuvant RT or CTRT was permitted only if <20% of patients received it, 
and data of patients that received adjuvant CT only were provided. No experimental 
agents were permitted. Studies had to include patients who underwent curative-intent 
surgery alone (R0-R1) as a comparator group. Curative-intent resections were defined as 
those in which no macroscopic disease (R2) remained, thus excluding studies that 
included palliative surgery if palliative surgeries were the majority. Studies in which 
differentiation between curative and palliative resections was not possible were excluded, 
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as well as studies involving patients undergoing liver transplantation or neoadjuvant 
CT(RT).  
To avoid inclusion of overlapping series in duplicate publications only the larger or more 
complete publication was included.  
 
Data analysis 
Two authors (MG and FP) independently extracted information using predefined 
Microsoft word-based forms. The following details were extracted: study period, country, 
patient number and disease site (intrahepatic versus extrahepatic cholangiocarcinoma 
versus gallbladder). Where reported, stage, rate of surgeries and type of CT were 
collected. Efficacy outcomes collected included median and 5-year OS. An additional 
reviewer (GT) resolved any discrepancies regarding the extraction of data. Also hazard 
ratios (HR) for survival, calculated from multivariate (preferred) or univariate analysis 
and associated with receipt or not of adjuvant CT were extracted from articles. Quality of 
publications was expressed through Nottingham-Ottawa-Scale (NOS) for retrospective 
and observational studies (4), and with Jadad score for randomized studies (5). 
The survival benefit between AT and no AT was expressed as a hazard ratio (HR) and its 
95% CI, extracted from multivariate analysis if available. Pooled median OS difference was 
also calculated. Subgroup analysis and meta-regression was performed to account for year 
of publication, number of patients (>200 vs < 200), nodal positive disease patients rate, rate 
of radical surgery, receipt of adjuvant RT, race and subsite (cholangiocarcinoma vs 
gallbladder). Publication bias was evaluated using Begg’s rank correlation test (6), Egger’s 
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regression test (7) and trim and Fill method (8). Data were extracted from the primary 
publications and combined into a meta-analysis using RevMan 5.3 analysis software 
(Cochrane Collaboration, Copenhagen, Denmark) and Comprehensive Meta Analysis 
software v3.3.3070. Pooled estimates of HRs were computed using the random-effect 
model (9). Because of expected intra study heterogeneity, studies were weighted by the 
generic inverse variance approach (10).  
 
Results  
A total of 30 studies were eligible for inclusion in the meta-analysis (Fig 1) (11-40). These 
studies incorporated 22499 patients of whom 3967 (17.6%) received AC (Table 1). Of the 
included studies, two were prospective series (13, 14), one a randomized study (34) and 27 
retrospective patient series (11, 12, 15-33, 35-40). Ten cohorts included Japanese patients 
(18, 19, 24, 25, 29-32, 34, 37) nine series were from United States of America (14, 15, 17, 20, 
22, 23, 27, 28, 33), three from Korea (13, 21, 26) and China (35, 39, 40), two from Thailand 
(12, 36), one from Taiwan (38) and two were European series (from Germany (11) and Italy 
(16)). Most surgeries of primary tumors were R0 or R1, with some publications that 
included few palliative or R2 interventions. Indeed, only four studies reported a R2 
resection rate >20%) (12, 32, 34, 38), while palliative surgery was mentioned in a series only 
(40).  
Mean difference in survival and overall risk of death  
Data for mean difference in OS were available for n=13 studies. Weighted mean OS 
difference among experimental (AC) and control arm was 4.3 months (95%CI 0.88-7.79, 
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P=0.014 according to random effect model). Overall data for OS analysis (HR for OS) was 
available in n=22 studies. AC reduced the risk of death by 41% (HR=0.59, 95%CI 0.49-0.71; 
p<0.001). The four studies including a R2 resection rate >20% did not affect the OS 
analysis, with a resulting HR of 0.61 when these series were not considered. Heterogeneity 
was high (I2=82%, P<0.001) so random effect model was used (Fig.2) (9). 
Meta-regression analysis 
Analysis of survival according to year of publication (2008-2012 and > 2012) did not 
change significantly the final results. The magnitude of benefit was less in studies with > 
of 200 patients (HR=0.77, 95%CI 0.65-0.91, P=0.002) compared to those with < 200 patients 
(HR=0.46, 95%CI 0.35-0.61; P<0.001). Overall, the main effect was not influenced by site 
(cholangiocarcinoma vs gallbladder carcinoma), nodal status, rate of radical surgeries (R0 
and R1) and by race. Instead the magnitude of benefit was inferior in those studies were 
patients received RT in addition to adjuvant CT (slope 1.5, 95%CI -0.04-3.08, P=0.02). The 
value of the slope indicates that for each 1% of RT use, the benefit (log HR) decreases, on 
average, by 1.5 points.   
Publication bias 
Observation of funnel plot (Fig.3) showed evidence of publication bias (Begg’s test p=0.01) 
(6). Similarly Egger’s test was significant (P<0.001) (7). According to the Trim and Fill 
method the final result according to random effect model is 0,72 (95%CI 0,6-0.85) (8). 
Under the one-study-removed procedure, the final HR ranged from 0.56 (removing Glazer 
et al. study (17)) and 0.61 (removing Liu et al. study (40)).  
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Discussion  
This meta-analysis included 30 studies (involving more than 22,499 patients) and assessed 
the impact of AC for resected biliary tract cancers.  
The main analysis reported a 41% reduction in the risk of death that translated in a mean 
OS benefit of 4 months in an unselected population of both Asiatic and Caucasian patients. 
According to the meta-regression analysis, the magnitude of benefit was not influenced 
by: radical surgery, nodal status, subsite, race, year of publication or sample of studies. 
Moreover, the meta-regression analysis revealed an inferior benefit in OS in patients given 
adjuvant RT in combination with CT. This means that adjuvant CTRT cannot be viewed as 
a standard practice, and may be reserved to those patients with gross margin positive 
disease (R1/2) to reduce local progression. This conclusion is in line with the previous 
meta-analysis of Horgan et al.,that showed that adjuvant RT seems to benefit only patients 
with R1 resections with a possible detrimental effect in R0 disease, and AC alone being 
beneficial in nodal positive disease where it can be considered a possible standard of care 
in resected biliary tract cancers. Similarly, another meta-analysis of retrospective studies in 
gallbladder cancer revealed a survival benefit only for node-positive, R1 and stage II or 
higher disease. This meta-analysis, however, included only 2 studies of AC (41). A further 
meta-analysis on resected distal cholangiocarcinoma reported similar 5-year survival rate 
between patients receiving and not receiving AC (42).  
The mainstay of treatment for localized cholangiocarcinomas is surgery, with node-
positive disease and involved surgical margins being the poorer prognostic factors in both 
hilar and intrahepatic cancers and a median survival of about 2 years (43, 44) (45) (46) (47). 
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Both ESMO and NCCN guidelines agree on the lack of evidence-based indication for 
adjuvant treatment in resected biliary tract cancers. The choice should be driven by a 
patient-by-patient risk-benefit evaluation (2, 3). Among these different regimens, a meta-
analysis reported a superior survival outcome given by gemcitabine over 5-fluorouracil 
CT and combined CTRT, with a higher 1-year and 5-year OS and a better toxicity profile in 
terms of haematological and nonhaematological effects  (48).  
Three randomized phase III studies considering different adjuvant strategies in resected 
BTC have recently closed patients’ accrual or are still ongoing. Results the phase III trial 
PRODIGE 12-ACCORD 18 (observation versus gemcitabine/oxaliplatin [GEMOX] in 
resected BTC), showed a non-significant difference in relapse-free survival (RFS) between 
adjuvant chemotherapy and surveillance (49). The BILCAP study (observation versus 
adjuvant capecitabine) is no longer recruiting and results are awaited (50) while the 
ACTICCA-1 study (observation versus gemcitabine/cisplatin) is currently randomizing 
patients (51). 
This meta-analysis has some intrinsic limitations. First, it includes mainly retrospective 
patient series so that patients with more extended disease and good performance status 
may have received further therapies after surgery. Secondly, the analysis included 19 
Asiatic studies with potentially different response to cytotoxic or different surgical skill. 
Thirdly, it does not define the preferred regimen to be adopted as the standard of care in 
these patients, because various regimens have been used in the publications included. 
Moreover, even studies with small series could have introduced bias and could have 
slightly enlarged the resulted benefit. Low-powered studies are more likely to provide a 
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wide range of estimates of the magnitude of an effect, so the effect size observed could be 
less pronounced or neutral in prospective-randomized studies. For instance, in the 
recently presented PRODIGE 12-ACCORD 18, an 8-month non-significant benefit in 
relapse-free survival (RFS) was reported . However, this is the first meta-analysis that has 
addressed the value of systemic chemotherapy alone as AT in resected BTC. It included a 
survival analysis with HR as a adequate measure of clinical benefit. And finally, through 
meta-regression and random effect model, the source of heterogeneity was taken into 
consideration without finding an explicit variable (except addition of RT) not associated 
with a survival benefit. Despite this, significant publication bias emerged from Begg’s and 
Egger’s test, and different study designs, characteristics of included patients and various 
regimens adopted as adjuvant therapy could have substantially contributed to observe 
heterogeneity among publications.  
In conclusion, this meta-analysis of 30 studies including more than 20,000 patients showed 
a considerable benefit coming from AC. Indeed, adjuvant treatment reduced the risk of 
death by 40% and this translated in an absolute mean OS gain of 4 months in unselected 
patients with cholangiocarcinoma and gallbladder cancers.  
While the PRODIGE 12-ACCORD 18 study failed to show a RFS advantage in patients 
treated with adjuvant gemcitabine and oxaliplatin, final results of the BILCAP and 
ACTICCA-1 studies are awaited in order to provide more evidence on this controversial 
topic.  
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